We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other cheap ...

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...

The fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Analysts have previously suggested that Lumakras could become a $1 billion-plus product if Amgen can extend the label for the drug into the first-line NSCLC setting and also get approval for the ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...